Abstract
Background SARS-CoV-2 continues to spread despite fast vaccine rollout, which could be attributed to waning immunity or to a reduced protection against some variants. A thorough characterization of vaccine protection and its duration in time is needed to inform vaccination policies and enhance public trust.
Methods We matched three national databases with exhaustive information on screening, vaccination and hospitalizations in France over the year 2021. We performed a two-step analysis to estimate vaccine effectiveness against severe forms of Covid-19 in people aged 50 years or over, combining: (i) a test-negative case–control design to assess vaccine effectiveness against symptomatic infections; and (ii) a survival analysis to assess the additional protection against severe outcomes (hospitalizations and inpatient deaths) in infected individuals.
Results We found a high vaccine effectiveness in people aged 50 years or more, reaching 82% against symptomatic infections and 94% against severe outcomes, after a full vaccination scheme.
Vaccine effectiveness against symptomatic infections strongly decreased over time, dropping to 53% after six months, but remained high against severe forms (90% after six months). The booster dose allowed restoring high protection levels. Vaccine protection and its evolution in time, showed little difference against the variants that circulated prior to December 2021 in France, including the Delta variant.
Conclusion Though vaccine immunity decreases over time, vaccination remains crucial to provide individual protection against severe diseases. This decline can be reversed by the injection of a booster dose.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We acknowledge financial support from the French Ministry for Solidarity and Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data collections and transmissions to the Drees are covered by the following decrees which were reviewed by the French Data Protection Authority (CNIL): precisely for each data source, VAC-SI (Décret 2020-1690 du 25 décembre 2020, CNIL deliberation of the 10th of December 2020), SI-DEP (Décret 2020-551 du 12 mai 2020, CNIL deliberation of the 8th of May 2020), SI-VIC (Décret 2018-175 du 9 mars 2018, CNIL deliberation of the 7th of July of 2016 modified with the deliberation of the 7th of December 2017; National Council of Statistical Information (CNIS), deliberation of the 8th of December 2020). The DREES is allowed to process personal health data in order to compute statistics, under article 65 of the law Data processing and Liberties (Informatique et Libertés) of January 6th, 1978. All data processing and storage comply with the General Data Protection Regulation (GDPR).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data was obtained to carry out the legal missions of the DREES (health surveillance and alert, healthcare performance assessment), and therefore benefited from the legal prerogatives vested in the French Ministry for Solidarity and Health to carry out these missions.
